Text Size:AAA


Sino Biological offers quality reagents for matrix metalloproteinase related study, including recombinant proteins, antibodies, ELISA kits, and ORF cDNA clones.

Product CategoriesProteinsAntibodiesELISA KitscDNA Clones
Number of Products

基质金属蛋白酶(MMP) Related Products Index

基质金属蛋白酶(MMP) Related Products by Product Type

基质金属蛋白酶(MMP) By Species

基质金属蛋白酶(MMP) by Signaling Pathways

基质金属蛋白酶(MMP) Background

Matrix metalloproteinases (MMPs), a subfamily of metalloproteinases, are zinc-dependent endopeptidases. They share a common domain structure. The three common domains are the pro-peptide, the catalytic domain and the haemopexin-like C-terminal domain which is linked to the catalytic domain by a flexible hinge region. Matrix metalloproteinases are characterized by their ability of degrading extracellular matrix proteins, but they can also process a number of bioactive molecules. Matrix metalloproteinases are involved in the cleavage of cell surface receptors, the release of apoptotic ligands (such as the FAS ligand), as well as chemokines and cytokines. Matrix metalloproteinases are also thought to play a major role in a variety of biological processes, such as cell differentiation and proliferation, cell migration/adhesion, apoptosis, angiogenesis, and host defense (innate immunity). Loss of the exquisite control of the MMP system leads to extensive and often destructive degradation of the extracellular matrix as seen in arthritis, cancer, congestive heart failure, and osteoarthritis. On the basis of their massive up-regulation in malignant tissues and their unique ability to degrade all components of the extracellular matrix, matrix metalloproteinases have been heralded as promising targets for cancer therapy. Matrix metalloproteinases are inhibited by specific endogenous tissue inhibitor of metalloproteinases (TIMPs), which comprise a family of four protease inhibitors: TIMP-1, TIMP-2, TIMP-3 and TIMP-4. Other natural inhibitors of MMPs include α2-macroglobulin (α2M) and endostatin.

基质金属蛋白酶(MMP) References

    1. Klein G, et al. (2004) The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol. 50(2):87-100.
    2. Van Lint P, et al. (2007) Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol. 82(6):1375-81.
    3. Motrescu ER, et al. (2008) Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle. Biol Chem. 389(8):1037-41.
    4. Lia NG, et al. (2009) Selective matrix metalloproteinase inhibitors for cancer. Curr Med Chem. 16(29):3805-27.